

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

PAR PHARMACEUTICAL, INC., )  
PAR STERILE PRODUCTS, LLC, and )  
ENDO PAR INNOVATION )  
COMPANY, LLC, )

Plaintiffs,

V.

EAGLE PHARMACEUTICALS INC., )  
)  
Defendant. )

C.A. No. 18-823-CFC-JLH

**LETTER TO THE HONORABLE COLM F. CONNOLLY  
FROM BINDU A. PALAPURA**

OF COUNSEL:

Jay P. Lefkowitz, P.C.  
 Jeanna M. Wacker  
 Benjamin A. Lasky  
 Sam Kwon  
 Christopher J. Citro  
 Matthew Lembo  
 KIRKLAND & ELLIS LLP  
 601 Lexington Avenue  
 New York, NY 10022  
 Tel: (212) 446-4800

**Bryan S. Hales**  
**KIRKLAND & ELLIS LLP**  
300 North LaSalle  
Chicago, IL 60654  
Tel: (312) 862-2000

David E. Moore (#3983)  
Bindu A. Palapura (#5370)  
Stephanie E. O'Byrne (#4446)  
POTTER ANDERSON & CORROON LLP  
Hercules Plaza, 6<sup>th</sup> Floor  
1313 N. Market Street  
Wilmington, DE 19801  
Tel: (302) 984-6000  
[dmoore@potteranderson.com](mailto:dmoore@potteranderson.com)  
[bpalapura@potteranderson.com](mailto:bpalapura@potteranderson.com)  
[sobyrne@potteranderson.com](mailto:sobyrne@potteranderson.com)

*Attorneys for Defendant Eagle  
Pharmaceuticals Inc.*

Dated: June 8, 2021  
7221902/ 45185



1313 North Market Street  
P.O. Box 951  
Wilmington, DE 19801-0951  
302 984 6000  
[www.potteranderson.com](http://www.potteranderson.com)

Bindu A. Palapura  
Partner  
Attorney at Law  
[bpalapura@potteranderson.com](mailto:bpalapura@potteranderson.com)  
302 984-6092 Direct Phone  
302 658-1192 Firm Fax

June 8, 2021

**VIA ELECTRONIC FILING**

The Honorable Colm F. Connolly  
United States District Judge  
J. Caleb Boggs Federal Building  
844 N. King Street  
Unit 31, Room 4124  
Wilmington, DE 19801-3555

[REDACTED]

Re: *Par Pharm., Inc. v. Eagle Pharm., Inc.*, C.A. No. 18-823-CFC

Dear Judge Connolly:

We respectfully submit this letter on behalf of Defendant Eagle to correct a number of important factual inaccuracies contained in Par's letter filed earlier today.

First, Par implies that Eagle will not be able to make its FDA submission in mid-June, referencing "public statements by Eagle's CEO [that] indicate that it has not yet completed the next round of animal testing, let alone analyzed the results." (*Id.* at 1). Par is incorrect. Eagle is not conducting any vasopressin animal studies at this time and none are planned. Indeed, in the statement from last week that Par appears to reference, Eagle's CEO reconfirmed the mid-June timing:

We have this one last study that we are waiting to report out hopefully any day now. Assuming that those results are the way they have been in the past and what we expect, we will be wrapping this all up. And we have been saying by mid-year, you know ***which is obviously this month we will be fully responding to this CRL. . .***

Statement of S. Tarriff, Jefferies Healthcare Conference (June 2, 2021).

[REDACTED]

The Honorable Colm F. Connolly

June 8, 2021

Page 3

[REDACTED]

Par did not make this proposal to Eagle. Instead, as discussed in Eagle's letter from earlier today, Par proposed Eagle drop its invalidity and unenforceability case, which Eagle cannot accept for the reasons explained. (D.I. 251 at 2-3).

[REDACTED]

Eagle has not had any exchanges with the FDA since the May 26 teleconference with the Court.

Respectfully,

*/s/ Bindu A. Palapura*

Bindu A. Palapura

BAP/mas/7221902/45185

cc: Clerk of the Court (via hand delivery)  
Counsel of Record (via electronic mail)